Sumitomo Pharma Co., Ltd. (4506) Stock Price

Sumitomo Pharma's primary business is the manufacturing, procurement, and sale of prescription pharmaceuticals. Within Japan, Sumitomo Pharma Promo Co., Ltd. manufactures and sells authorized generic drugs. Additionally, S-RACMO Co., Ltd. is a joint venture with Sumitomo Chemical that provides contract development and manufacturing services in the regenerative and cell medicine field.

RACTHERA is a joint venture established through co-investment with Sumitomo Chemical, conducting research and development in the regenerative and cell medicine field. The company also operates subsidiaries and affiliated companies that provide services such as pharmaceutical storage and distribution. Through these operations, Sumitomo Pharma delivers a diverse range of pharmaceutical-related services.

In North America, multiple companies including Sumitomo Pharma America, Inc. engage in the manufacturing, procurement, and sale of prescription pharmaceuticals. In Europe, companies such as Sumitomo Pharma Switzerland GmbH conduct similar operations. Through these entities, Sumitomo Pharma operates its pharmaceutical business on a global scale.

In Asia, Sumitomo Pharma Investment (China) Co., Ltd. manages local operations in China, while Sumitomo Pharma (Suzhou) Co., Ltd. handles the manufacturing and sale of prescription pharmaceuticals. Additionally, Sumitomo Pharma Asia Pacific Pte. Ltd. and other entities conduct pharmaceutical import, sales, and information provision in Southeast Asia and Taiwan. Through these operations, the company actively expands its business across Asian markets.

Sumitomo Pharma is committed to creating new value through research and development and contributing to society. The company focuses on psychiatry/neurology and oncology as priority therapeutic areas, aiming to improve people's health through diverse approaches. By 2033, the company aims to establish itself as a "Global Specialized Player (GSP)".

Sumitomo Pharma formulated its "Medium-Term Management Plan 2027" in 2023. However, in response to changing business conditions, the company withdrew this plan and announced "Reboot 2027 ~ Sumitomo Pharma's Renewed Growth Momentum ~" in 2025. This plan targets renewed growth through efficient organizational operations and improved success rates in research and development.

Sumitomo Pharma is focused on maximizing the value of core products in the North American market. The company is expanding market share for advanced prostate cancer treatment Orgovyx, uterine fibroid treatment Myfembree, and overactive bladder treatment Gemtesa. In the Japanese market, the company is promoting value maximization of antipsychotic Latuda and diabetes treatment Twymeg.

Looking ahead to future growth, Sumitomo Pharma is prioritizing new drug development in oncology. The company is prioritizing the development of enzomenib and nuvisertib, targeting early regulatory approval. In psychiatry/neurology, the company is advancing the practical application of iPS cell-derived products to realize innovative treatments.

Sumitomo Pharma is advancing "Sustainability Management" to contribute to a sustainable society. The company shares its mission and values across the group and conducts honest business activities to drive sustained corporate value enhancement. Through this approach, the company aims to continue providing new value to patients and society.